Article

New Drug Class Shows Promise in Melanoma

Thiazole benzensulfonamides (TZB) show useful anticancer properties.

A new family of drugs was discovered that can help treat melanoma, a study published in Cancer Cell found.

Targeted therapies and immunotherapies have been used to treat metastatic melanoma, however most patients need further treatment to stop the tumor from coming back.

The newly discovered family of drugs called thiazole benzensulfonamides (TZB) have useful anticancer properties.

“Initially this family of drugs was identified in type 2 diabetes, as it increased the sensitivity of cells to insulin,” said lead researcher Stéphane Rocchi. “If we wanted to use it against cancer, we had to be able to eliminate this proinsulin activity. Thus we started to modify its structure.”

The experiment took numerous attempts, but researchers were able to extensively modify the initial TZD structure to obtain a formulation with the lead compound HA15.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards